Biofrontera Inc
NASDAQ:BFRI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BCM Resources Corp
XBER:H1E
|
CA |
Biofrontera Inc
Other
Biofrontera Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biofrontera Inc
NASDAQ:BFRI
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other
-$260m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-16%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other
-$128m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-30%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other
-$459m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other
-$131m
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other
-$772m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-31%
|
|
Biofrontera Inc
Glance View
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2021-10-14. The firm is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. The company also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.
